Technical Analysis for ACLX - Arcellx, Inc.

Grade Last Price % Change Price Change
C 7.61 -14.59% -1.30
ACLX closed down 14.59 percent on Monday, May 16, 2022, on 57 percent of normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Down Down

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
New 52 Week Closing Low Bearish 0.00%
Expansion Breakdown Bearish Swing Setup 0.00%
New 52 Week Low Weakness 0.00%
MACD Bullish Signal Line Cross Bullish -14.59%
Stochastic Reached Oversold Weakness -14.59%
Wide Bands Range Expansion -14.59%
Gapped Up Strength -14.59%
Oversold Stochastic Weakness -14.59%
NR7 Range Contraction -13.52%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Fell Below Lower Bollinger Band about 5 hours ago
Lower Bollinger Band Support about 5 hours ago
Down 1 ATR about 5 hours ago
Down 10% about 6 hours ago
New 52 Week Low about 6 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Arcellx, Inc. Description

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. Its lead ddCAR product candidate is CART-ddBCMA, which is in Phase 1 clinical development for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). The company is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Organ Systems Acute Myeloid Leukemia Immunotherapies Multiple Myeloma Protein Kinase Inhibitor Antibody Drug Conjugate Myelodysplastic Syndrome

Is ACLX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 19.92
52 Week Low 7.15
Average Volume 101,666
200-Day Moving Average 0.00
50-Day Moving Average 12.95
20-Day Moving Average 10.13
10-Day Moving Average 8.94
Average True Range 1.09
RSI 27.54
ADX 34.12
+DI 11.16
-DI 31.92
Chandelier Exit (Long, 3 ATRs) 9.94
Chandelier Exit (Short, 3 ATRs) 10.41
Upper Bollinger Bands 12.83
Lower Bollinger Band 7.43
Percent B (%b) 0.03
BandWidth 53.31
MACD Line -1.33
MACD Signal Line -1.29
MACD Histogram -0.0395
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.01
Resistance 3 (R3) 10.12 9.44 9.61
Resistance 2 (R2) 9.44 8.83 9.38 9.48
Resistance 1 (R1) 8.52 8.45 8.18 8.41 9.34
Pivot Point 7.84 7.84 7.67 7.78 7.84
Support 1 (S1) 6.92 7.23 6.58 6.81 5.88
Support 2 (S2) 6.24 6.85 6.18 5.74
Support 3 (S3) 5.32 6.24 5.61
Support 4 (S4) 5.21